SG11201805729SA - Therapeutic compositions and methods for treating hepatitis b - Google Patents
Therapeutic compositions and methods for treating hepatitis bInfo
- Publication number
- SG11201805729SA SG11201805729SA SG11201805729SA SG11201805729SA SG11201805729SA SG 11201805729S A SG11201805729S A SG 11201805729SA SG 11201805729S A SG11201805729S A SG 11201805729SA SG 11201805729S A SG11201805729S A SG 11201805729SA SG 11201805729S A SG11201805729S A SG 11201805729SA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- therapeutic compositions
- treating hepatitis
- hepatitis
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662276722P | 2016-01-08 | 2016-01-08 | |
| US201662343514P | 2016-05-31 | 2016-05-31 | |
| US201662345476P | 2016-06-03 | 2016-06-03 | |
| US201662409180P | 2016-10-17 | 2016-10-17 | |
| US201662420969P | 2016-11-11 | 2016-11-11 | |
| PCT/US2017/012614 WO2017120527A2 (en) | 2016-01-08 | 2017-01-06 | Therapeutic compositions and methods for treating hepatitis b |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805729SA true SG11201805729SA (en) | 2018-08-30 |
Family
ID=59274445
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805729SA SG11201805729SA (en) | 2016-01-08 | 2017-01-06 | Therapeutic compositions and methods for treating hepatitis b |
| SG10201912314QA SG10201912314QA (en) | 2016-01-08 | 2017-01-06 | Therapeutic compositions and methods for treating hepatitis b |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201912314QA SG10201912314QA (en) | 2016-01-08 | 2017-01-06 | Therapeutic compositions and methods for treating hepatitis b |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20190282604A1 (en) |
| EP (1) | EP3400008A4 (en) |
| JP (2) | JP2019501202A (en) |
| KR (1) | KR20180120675A (en) |
| CN (1) | CN110022895A (en) |
| AU (2) | AU2017205650A1 (en) |
| BR (1) | BR112018013928A2 (en) |
| CA (1) | CA3009996A1 (en) |
| CL (2) | CL2018001858A1 (en) |
| CO (1) | CO2018008249A2 (en) |
| HK (1) | HK1255835A1 (en) |
| IL (2) | IL303754A (en) |
| PH (1) | PH12018501455A1 (en) |
| SG (2) | SG11201805729SA (en) |
| TW (3) | TW201735950A (en) |
| WO (1) | WO2017120527A2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020214974A1 (en) * | 2019-04-18 | 2020-10-22 | Janssen Pharmaceuticals, Inc. | Combination therapy for treating hepatitis b virus infection |
| US20200330499A1 (en) * | 2019-04-18 | 2020-10-22 | Janssen Pharmaceuticals, Inc. | Combination therapy for treating hepatitis b virus infection |
| EP4081217A1 (en) * | 2019-12-24 | 2022-11-02 | F. Hoffmann-La Roche AG | Pharmaceutical combination of antiviral agents targeting hbv and/or an immune modulator for treatment of hbv |
| CN117771361A (en) * | 2024-02-27 | 2024-03-29 | 天津中逸安健生物科技有限公司 | Lipid nanoadjuvant of polyinosinic acid-polycytidylic acid compound, and preparation method and application thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2319713C (en) * | 1998-02-12 | 2012-06-26 | G.D. Searle & Co. | Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections |
| EP2318031A4 (en) * | 2008-06-03 | 2012-09-12 | Aethlon Medical Inc | Enhanced antiviral therapy methods and devices |
| RU2624045C2 (en) * | 2010-08-17 | 2017-06-30 | Сирна Терапьютикс,Инк | RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| US8993771B2 (en) * | 2013-03-12 | 2015-03-31 | Novira Therapeutics, Inc. | Hepatitis B antiviral agents |
| WO2015172128A1 (en) * | 2014-05-09 | 2015-11-12 | Indiana University Research And Technology Corporation | Methods and compositions for treating hepatitis b virus infections |
| US10358447B2 (en) * | 2017-12-04 | 2019-07-23 | Arbutus Biopharma Corporation | Substituted 2-N-hydroxy-1,3-dioxo-1,2,3,4-tetrahydronaphthyridines, and methods of making and using same |
| US10550084B2 (en) * | 2017-12-04 | 2020-02-04 | Arbutus Biopharma Corporation | Substituted 1-hydroxy-pyridin-2(1H)-ones, and methods of making and using same |
-
2017
- 2017-01-06 US US16/068,243 patent/US20190282604A1/en not_active Abandoned
- 2017-01-06 CA CA3009996A patent/CA3009996A1/en active Pending
- 2017-01-06 AU AU2017205650A patent/AU2017205650A1/en not_active Abandoned
- 2017-01-06 JP JP2018535880A patent/JP2019501202A/en active Pending
- 2017-01-06 EP EP17736471.8A patent/EP3400008A4/en active Pending
- 2017-01-06 CN CN201780014167.5A patent/CN110022895A/en active Pending
- 2017-01-06 IL IL303754A patent/IL303754A/en unknown
- 2017-01-06 SG SG11201805729SA patent/SG11201805729SA/en unknown
- 2017-01-06 KR KR1020187022434A patent/KR20180120675A/en active Search and Examination
- 2017-01-06 IL IL295692A patent/IL295692A/en unknown
- 2017-01-06 WO PCT/US2017/012614 patent/WO2017120527A2/en active Application Filing
- 2017-01-06 SG SG10201912314QA patent/SG10201912314QA/en unknown
- 2017-01-06 BR BR112018013928A patent/BR112018013928A2/en unknown
- 2017-01-09 TW TW106100606A patent/TW201735950A/en unknown
- 2017-01-09 TW TW110121989A patent/TW202211912A/en unknown
- 2017-01-09 TW TW111130283A patent/TW202322791A/en unknown
-
2018
- 2018-07-06 PH PH12018501455A patent/PH12018501455A1/en unknown
- 2018-07-06 CL CL2018001858A patent/CL2018001858A1/en unknown
- 2018-08-03 CO CONC2018/0008249A patent/CO2018008249A2/en unknown
- 2018-11-21 HK HK18114911.7A patent/HK1255835A1/en unknown
-
2022
- 2022-04-12 JP JP2022065611A patent/JP2022087209A/en active Pending
- 2022-06-02 AU AU2022203814A patent/AU2022203814A1/en active Pending
- 2022-11-29 US US18/071,353 patent/US20240050463A1/en active Pending
-
2023
- 2023-03-28 CL CL2023000892A patent/CL2023000892A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG10201912314QA (en) | 2020-02-27 |
| EP3400008A2 (en) | 2018-11-14 |
| WO2017120527A2 (en) | 2017-07-13 |
| HK1255835A1 (en) | 2019-08-30 |
| JP2022087209A (en) | 2022-06-09 |
| US20240050463A1 (en) | 2024-02-15 |
| CL2018001858A1 (en) | 2018-11-23 |
| TW202211912A (en) | 2022-04-01 |
| TW201735950A (en) | 2017-10-16 |
| AU2022203814A1 (en) | 2022-06-23 |
| AU2017205650A1 (en) | 2018-07-19 |
| CL2023000892A1 (en) | 2023-09-29 |
| KR20180120675A (en) | 2018-11-06 |
| IL295692A (en) | 2022-10-01 |
| CA3009996A1 (en) | 2017-07-13 |
| BR112018013928A2 (en) | 2018-12-11 |
| TW202322791A (en) | 2023-06-16 |
| CN110022895A (en) | 2019-07-16 |
| IL303754A (en) | 2023-08-01 |
| CO2018008249A2 (en) | 2018-08-21 |
| PH12018501455A1 (en) | 2019-03-18 |
| WO2017120527A3 (en) | 2017-08-31 |
| EP3400008A4 (en) | 2019-10-09 |
| US20190282604A1 (en) | 2019-09-19 |
| JP2019501202A (en) | 2019-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267247B (en) | Compositions and methods for treating cancer | |
| IL258697A (en) | Crispr/cas-related methods and compositions for treating hepatitis b virus | |
| IL260525B (en) | Means and methods for treating hbv | |
| IL304820A (en) | Compositions and methods for treating cancer | |
| IL266053A (en) | Compositions and methods for treating ezh2-mediated cancer | |
| PT3377516T (en) | Methods and compositions for treating cancer | |
| IL251759B (en) | Compositions and methods for treating insomnia | |
| IL263460A (en) | Compositions and methods for treating cardiovascular disease | |
| ZA201900960B (en) | Methods and compositions for the treatment of cancer | |
| HK1250480A1 (en) | Compositions and methods for the treatment of hbv infection | |
| IL256523A (en) | Compositions and methods for treating cancer | |
| EP3634431A4 (en) | Therapeutic compositions and methods for treating hepatitis b | |
| IL288768A (en) | Compositions and methods for treating celiac sprue disease | |
| IL263218A (en) | Composition and methods for microbiota therapy | |
| HK1255835A1 (en) | Therapeutic compositions and methods for treating hepatitis b | |
| SG10202013112YA (en) | Zinc-gamma-pga compositions and methods for treating cancer | |
| ZA201808232B (en) | Compositions and methods for the treatment of cancer | |
| IL255638A (en) | Compositions and methods for treating cancer | |
| EP3519058C0 (en) | Compositions and methods for treating hair | |
| HK1255695A1 (en) | Composition and methods for the treatment of blepharoptosis | |
| ZA201802268B (en) | Methods and compositions for preventing or treating cancer | |
| ZA201904626B (en) | Cancer treatment method and composition | |
| HK1250958A1 (en) | Compositions and methods for treating cancer | |
| GB201521083D0 (en) | Compositions for treatment and methods thereof |